Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer
This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.
Breast Cancer|Metastasis
DRUG: Capecitabine and Mitomycin C
Response rate, average 5 years
time to disease progression, average 5 years|overall survival, average 5 years|Toxicity, average 5 years
This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.